Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.

European journal of gastroenterology & hepatology - 1 Aug 2008

Raziorrouh Bijan, Jung Maria-Christina, Schirren Carl Albrecht, Loehe Florian, Thiel Manfred, Nitschko Hans, Diepolder Helmut, Ulsenheimer Axel, Heeg Malte, Zachoval Reinhart, Gruener Norbert Hubert

Abstract excerpt

OBJECTIVES: Recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) is a major cause of transplant failure in HCV-positive patients. We retrospectively assessed the efficacy and safety of antiviral therapy and determined the factors influencing sustained virologic response (SVR) in LT recipients. METHODS: Between 1998 and 2007, we treated 36 LT recipients for hepatitis C cirrhosis and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Administration Schedule
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Graft Survival

Share to Immunosuppressive Agents

Share to Interferon-alpha

Share to Liver Transplantation

Share to Recurrence

Share to Ribavirin

Source

Identifiers

PMID: 18617783
DOI: 10.1097/MEG.0b013e3282f762f8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.PMID 18617783Read ↗

Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome.Semantic proximity Read ↗

High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.Semantic proximity Read ↗

Interferon-alpha plus ribavirin for 12 months increases the sustained response rates in chronic hepatitis C relapsers.Semantic proximity Read ↗

Genotype 3 and higher low-density lipoprotein levels are predictors of good response to treatment of recurrent hepatitis C following living donor liver transplantation.Semantic proximity Read ↗

Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation.Semantic proximity Read ↗

Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study.Semantic proximity Read ↗

Recurrent hepatitis C genotype 1b following liver transplantation: treatment with combination interferon-ribavirin therapy.Semantic proximity Read ↗

Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C.Semantic proximity Read ↗

Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?Semantic proximity Read ↗

Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.Semantic proximity Read ↗

Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation.Semantic proximity Read ↗

A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.